SEARCH:   Advanced

Blood, 15 July 2006, Vol. 108, No. 2, pp. 618-621. Prepublished online as a Blood First Edition Paper on March 28, 2006; DOI 10.1182/blood-2005-10-4184. This Article Full Text (PDF) Supplemental Table All Versions of this Article: 2005-10-4184v1 108/2/618    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chang, D. H Articles by Dhodapkar, M. V Search for Related Content PubMed PubMed Citation Articles by Chang, D. H Articles by Dhodapkar, M. V Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 21, 2005 Accepted March 7, 2006 Enhancement of ligand dependent activation of human Natural Killer T cells by Lenalidomide: Therapeutic Implications David H Chang, Nancy Liu, Virginia Klimek, Hani Hassoun, Amitabha Mazumder, Stephen D Nimer, Sundar Jagannath, and Madhav V Dhodapkar* Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY, USA Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA St. Vincent's Cancer Center, New York, NY, USA Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY, USA; Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA * Corresponding author; email: dhodapm{at}rockefeller.edu. Natural-Killer T (NKT) cells are CD1d restricted glycolipid reactive innate lymphocytes that play an important role in protection from pathogens and tumors. Pharmacologic approaches to enhance NKT cell function will facilitate specific NKT targeting in the clinic. Here we show that lenalidomide (LEN), a novel thalidomide (Thal) analogue, enhances antigen-specific expansion of NKT cells in response to NKT ligand, -galactosyl-ceramide (-GalCer) in both healthy donors and myeloma patients. NKT cells activated in the presence of LEN have greater ability to secrete interferon-. Antigen-dependent activation of NKT cells was greater in the presence of dexamethasone (DEX) plus LEN, than with DEX alone. Therapy with LEN / Thal also led to an increase in NKT cells in vivo in patients with myeloma and del5q myelodysplastic syndrome. Together these data demonstrate that LEN and its analogues enhance CD1d mediated presentation of glycolipid antigens and support combining these agents with NKT targeted approaches for protection against tumors. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. E. Witzig, P. H. Wiernik, T. Moore, C. Reeder, C. Cole, G. Justice, H. Kaplan, M. Voralia, D. Pietronigro, K. Takeshita, et al. Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., November 10, 2009; 27(32): 5404 - 5409. [Abstract] [Full Text] [PDF] W. Song, H. J.J. van der Vliet, Y.-T. Tai, R. Prabhala, R. Wang, K. Podar, L. Catley, M. A. Shammas, K. C. Anderson, S. P. Balk, et al. Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy Clin. Cancer Res., November 1, 2008; 14(21): 6955 - 6962. [Abstract] [Full Text] [PDF] P. H. Wiernik, I. S. Lossos, J. M. Tuscano, G. Justice, J. M. Vose, C. E. Cole, W. Lam, K. McBride, K. Wride, D. Pietronigro, et al. Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., October 20, 2008; 26(30): 4952 - 4957. [Abstract] [Full Text] [PDF] D. H. Chang, H. Deng, P. Matthews, J. Krasovsky, G. Ragupathi, R. Spisek, A. Mazumder, D. H. Vesole, S. Jagannath, and M. V. Dhodapkar Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer Blood, August 15, 2008; 112(4): 1308 - 1316. [Abstract] [Full Text] [PDF] S. D. Nimer Myelodysplastic syndromes Blood, May 15, 2008; 111(10): 4841 - 4851. [Abstract] [Full Text] [PDF] A. A. Chanan-Khan and B. D. Cheson Lenalidomide for the Treatment of B-Cell Malignancies J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552. [Abstract] [Full Text] [PDF] A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood, January 1, 2008; 111(1): 86 - 93. [Abstract] [Full Text] [PDF] J. Kis, P. Engelmann, K. Farkas, G. Richman, S. Eck, J. Lolley, H. Jalahej, M. Borowiec, S. C. Kent, A. Treszl, et al. Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus J. Leukoc. Biol., March 1, 2007; 81(3): 654 - 662. [Abstract] [Full Text] [PDF] J. E. Talmadge, R. K. Singh, I. J. Fidler, and A. Raz Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer Am. J. Pathol., March 1, 2007; 170(3): 793 - 804. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020